Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers

• Status: Completed
• Trial end date: 2016-11-30
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to assess if the antimalarial drugs Dihydroartemisinine + Piperaquine (DP) are effective in preventing malaria infection for forest ranger

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Oxford University Clinical Research Unit, Vietnam
• Collaborators: Binh Phuoc Malaria Control Centre; Bu Gia Map National Park, Binh Phuoc Province, Vietnam
• Treatments: Artemisinins; Dihydroartemisinin; Piperaquine; Primaquine

Criteria

Inclusion Criteria:

1. Informed consent

2. Male, over or equal to18 years of age

3. Able and willing to comply with the study requirements and follow-up

Exclusion Criteria:

1. Inability to tolerate oral treatment

2. Previous episode of haemolysis or severe haemoglobinuria following primaquine

3. Glucose-6-phosphate dehydrogenase (G6PD) deficient with Hb < 9 g/dL *

4. Known hypersensitivity or allergy to any study drugs * If the participant with G6PD deficient gets malaria, primaquine would be used as recommended by World Health Organization (WHO) (once a week for 8 weeks) in combination with 3 days of chloroquine.